Relmada Therapeutics EBIT

Relmada Therapeutics (RLMD) currently reports a EBIT of $-63M as of June 2026. That compares with $-71M in the prior-year period — up 10.3% year over year. That is below the Consumer Discretionary sector average of $150B. Use the charts on this page to explore Relmada Therapeutics's EBIT history and peer comparisons.

Relmada Therapeutics's EBIT increased from $-71M to $-63M — a 10.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Relmada Therapeutics's EBIT of $-63M is lower than the Consumer Discretionary sector average of $150B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Relmada Therapeutics reported $-63M in EBIT as of June 2026. That compares with $-71M in the prior-year period — up 10.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-63M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Consumer Discretionary average is $150B. From there, open related valuation or income-statement pages for Relmada Therapeutics, and consider following RLMD for alerts when major investors trade the stock.